Initiate clinical trials evaluating IMVT-1402 in a total of ten indications
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 6 Feb 2025
- Due
- 31 Mar 2026
- Checked
- 17 Sep 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Immunovant anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026.”
What we found
Evidence strength A What the grades mean
By the March 31, 2026 deadline and for months afterward, Immunovant had initiated trials in only six of the ten committed IMVT-1402 indications, per its own filings.
-
A Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 Original source reaffirming the ten-indication by March 31, 2026 target
-
B Immunovant Provides Corporate Updates ... Second Quarter Ended September 30, 2025 Company describes IMVT-1402 development as six-indication program
-
D Immunovant's Q1 loss narrower than expected, pipeline in focus Confirms six disclosed indications still in place months after deadline
-
D Immunovant (NASDAQ: IMVT) shifts to IMVT-1402 with broad late-stage autoimmune program FY2026 10-K states six ongoing indications, future indications only 'to assess'
Checked 17 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Immunovant, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-IMVT-000361 · Corrections policy